Simone Song
Founder at ORI Capital Investment Advisory Hong Kong Ltd.
Net worth: 15 M $ as of 29/04/2024
Profile
Simone Song is the founder of ORI Capital Investment Advisory Hong Kong Ltd.
She is currently a Non-Executive Director at Kymab Ltd., a Director at TriSalus Operating Life Sciences, Inc., a Director at Orchard Therapeutics (Europe) Ltd., and a Director at Kymab Group Ltd.
Previously, she worked as a Managing Director at Cowen, Inc. and as an Independent Non-Executive Director at Orchard Therapeutics Plc.
Ms. Song holds a graduate degree from Claremont Graduate University and an undergraduate degree from Fudan University.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
02/04/2024 | 1,546,569 ( 5.78% ) | 15 M $ | 29/04/2024 |
Simone Song active positions
Companies | Position | Start |
---|---|---|
ORI Capital Investment Advisory Hong Kong Ltd.
ORI Capital Investment Advisory Hong Kong Ltd. Investment ManagersFinance ORI Capital Investment Advisory Hong Kong Ltd (ORI Capital) is a venture capital firm in Hong Kong. The firm was founded by Simone Song in 2015. The firm is headquartered in Hong Kong. | Founder | 31/12/2015 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Director/Board Member | - |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Director/Board Member | 21/12/2017 |
TriSalus Operating Life Sciences, Inc.
TriSalus Operating Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology TriSalus Operating Life Sciences, Inc. develops infusion systems for the interventional radiology and oncology markets. Its infusion systems are designed to deliver embolic agents through a micro-catheter with an expandable tip that collapses in forward flow and expands the vessel wall in reverse flow to increase targeted delivery, minimize reflux, and reduce damage to healthy tissue. The company was founded by Aravind Arepally and James E. Chomas in 2011 and is headquartered in Westminster, CO. | Director/Board Member | - |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Director/Board Member | 19/01/2017 |
Former positions of Simone Song
Companies | Position | End |
---|---|---|
COWEN INC. | Corporate Officer/Principal | - |
ORCHARD THERAPEUTICS PLC | Director/Board Member | - |
Training of Simone Song
Fudan University | Undergraduate Degree |
Claremont Graduate University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 7 |
---|---|
ORI Capital Investment Advisory Hong Kong Ltd.
ORI Capital Investment Advisory Hong Kong Ltd. Investment ManagersFinance ORI Capital Investment Advisory Hong Kong Ltd (ORI Capital) is a venture capital firm in Hong Kong. The firm was founded by Simone Song in 2015. The firm is headquartered in Hong Kong. | Finance |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Health Technology |
TriSalus Operating Life Sciences, Inc.
TriSalus Operating Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology TriSalus Operating Life Sciences, Inc. develops infusion systems for the interventional radiology and oncology markets. Its infusion systems are designed to deliver embolic agents through a micro-catheter with an expandable tip that collapses in forward flow and expands the vessel wall in reverse flow to increase targeted delivery, minimize reflux, and reduce damage to healthy tissue. The company was founded by Aravind Arepally and James E. Chomas in 2011 and is headquartered in Westminster, CO. | Health Technology |
Orchard Therapeutics Plc
Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
Cowen, Inc.
Cowen, Inc. Investment Banks/BrokersFinance Cowen, Inc. engages in the provision of financial services. It operates through following the segments: Operating Company and Asset Company. The Operating Company segment consists of the Cowen Investment Management, Investment Banking, Markets, and Research divisions. The Asset Company segment consists of the firm’s private investments, private real estate investments, and other legacy investment strategies. The firm offers investment banking services, equity and credit research, sales and trading, prime brokerage, global clearing, commission management services, and actively managed alternative investment products. The company was founded in 1918 and is headquartered in New York, NY. | Finance |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Health Technology |
- Stock Market
- Insiders
- Simone Song